Supreme Court keeps mail and telehealth access to mifepristone in place while legal challenge continues
The Facts
- The Supreme Court allowed mifepristone to continue being prescribed by telehealth and sent by mail while the legal case continues.
- The court's order blocks, for now, a May 1 Fifth Circuit ruling that would have restored an in-person dispensing requirement for mifepristone.
- The emergency appeal to the Supreme Court was filed by mifepristone manufacturers Danco Laboratories and GenBioPro.
- The underlying lawsuit was brought by Louisiana, which is challenging the FDA's policy allowing remote prescribing and mailing of mifepristone.
- Justices Clarence Thomas and Samuel Alito dissented from the Supreme Court's order.
- The ruling keeps current nationwide access to mifepristone in place during ongoing lower-court litigation, so there is no immediate change for patients while the case continues.
- Mifepristone is a widely used abortion medication and, with misoprostol, is the most common method of abortion in the United States, making the case consequential for access to abortion care.
- The legal dispute is not resolved: the Supreme Court's action is temporary, and the issue could return to the justices after further proceedings.
Context
What did the Supreme Court decide?
The court kept in place access to mifepristone by telehealth prescription and mail delivery while appeals continue, rather than letting the Fifth Circuit's restrictions take effect immediately BBC,NYT,Aol.
Who brought the case, and what policy is being challenged?
Louisiana sued over the FDA policy that allows mifepristone to be prescribed remotely and mailed to patients, and the manufacturers Danco Laboratories and GenBioPro asked the Supreme Court to block the lower-court restrictions Investing.com UK,Guardian,NBC News.
Where Left and Right agree, and where they split
- Where Left and Right agree
- The order preserves the status quo nationwide while the case continues, keeping telehealth prescribing and mailing of a widely used abortion medication available for now and ensuring no immediate change for patients during ongoing lower-court litigation.
- Where Left and Right split
- Less a disagreement than a question of emphasis: the practical effect on abortion access because mifepristone is widely used, versus the court’s temporary restraint and the unresolved challenge to the FDA’s policy continuing through lower courts.
How left and right read it
The most important point here is that current nationwide access remains in place, with no immediate change for patients, while the case continues. Because mifepristone is widely used and, with misoprostol, is the most common method of abortion in the United States, the court’s temporary order preserving telehealth prescribing and mailing has major implications for access to care.
What stands out is the court’s restraint: this order is temporary, blocks the Fifth Circuit’s May 1 ruling only for now, and leaves the underlying challenge to the FDA’s policy unresolved. For readers focused on process and institutional limits, it matters that Louisiana’s lawsuit will continue through lower-court litigation and that the issue could return to the justices later.
The receipts — 100 sources
Wire services (9)
Independent coverage (91)
The news, read by both sides.
The day’s biggest stories in one short brief, built to show both sides and the competing values behind the headlines. Free in your inbox.